Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Procept Biorobotics Corp (NQ: PRCT )

96.97 -0.10 (-0.10%)
Streaming Delayed Price Updated: 12:36 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 298,535
Open 96.80
Bid (Size) 96.92 (7)
Ask (Size) 97.20 (7)
Prev. Close 97.07
Today's Range 94.64 - 98.88
52wk Range 29.71 - 99.34
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire

Performance

YTD
+134.00%
+134.00%
1 Month
+39.28%
+39.28%
3 Month
+72.21%
+72.21%
6 Month
+57.85%
+57.85%
1 Year
+195.46%
+195.46%

More News

Read More
Royal Caribbean Sails Onto The IBD 50: Build Your List Of Stocks To Watch With These Top IBD Screens
Via Investor's Business Daily
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics's Earnings Outlook
Via Benzinga
Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
Via Benzinga
Topics Earnings
Exposures Financial
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Procept Biorobotics, A Top 5% Stock, Makes A Bullish Move On Quarterly Beat And Raise
Via Investor's Business Daily
PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
What Analysts Are Saying About PROCEPT BioRobotics Stock
Via Benzinga
Navigating 6 Analyst Ratings For PROCEPT BioRobotics
Via Benzinga
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
Via Benzinga
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
Jim Cramer Says This Retailer Yields 3%: 'Which Is Quite Good'
Via Benzinga
PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For PROCEPT BioRobotics
Via Benzinga
Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
Via Benzinga
Nasdaq Gains 0.5%; TJX Earnings Top Estimates
Via Benzinga
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
From PROCEPT BioRobotics
Via GlobeNewswire
3 Robotics Stocks to Sell in August Before They Crash & Burn
Via InvestorPlace
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
Via MarketBeat
Why Intuitive Surgical Stock is Dominating the Medical Sector
Via MarketBeat
PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.